ESMO 2023 Insights: "EV-302/KEYNOTE-A39 Study of Enfortumab Vedotin + Pembro vs. Chemo in Previously Untreated la/mUC"

272 views
October 30, 2023
0 Comments
Login to view comments. Click here to Login